Ramatillah Diana Laila, Gan Siew Hua, Novarticia Judith, Araminda Gena Nafta, Michael Michael, Elnaem Mohammad, Alawuddin Rizki, Khan Kashifullah
Faculty of Pharmacy, Universitas 17 Agustus 1945, Jakarta, Indonesia.
School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Bandar Sunway, Selangor, Malaysia.
Heliyon. 2024 Apr 26;10(9):e30087. doi: 10.1016/j.heliyon.2024.e30087. eCollection 2024 May 15.
The decreasing prevalence of COVID-19 has highlighted the value of vaccinations. CoronaVac® vaccine was one of the most widely used vaccines in Indonesia, in other Southeast Asian countries, as well as in Latin America. However, to date the safety and side effect profiles of CoronaVac® vaccine among the Indonesian population have not been reported.
In this study, the CoronaVac® safety profiles were determined in a community of a public health center in North Jakarta, Indonesia.
This is a descriptive cross-sectional questionnaire-based study on vaccine side effects as recorded in the yellow form (MESO). Patients (n = 300) who received CoronaVac® vaccinations between July and August 2021 were enrolled. SPSS was used to analyze the descriptive data.
Most respondents were women (72.7 %) between the ages of 17 and 21 years. A significantly (p = 0.009) positive correlation was established between the vaccine side effects (namely pain at the injection site) with the female gender. Other side effects such as fatigue (p = 0.034) and headache (p < 0.001) were also correlated with disease comorbidity.
Overall, the side effects following the first and the second doses were generally mild and included fever, pain in the injection area, fatigue, headache, drowsiness, diarrhea, cough, and nausea. Regarding vaccine efficacy, CoronaVac® confers better protection following the second dose administration where the percentage of respondents affected with COVID-19 (26.7 %) decreased to only 20.3 % following the second dose.
新冠病毒病（COVID-19）流行率的下降凸显了疫苗接种的价值。科兴新冠疫苗（CoronaVac®）是印度尼西亚、其他东南亚国家以及拉丁美洲使用最广泛的疫苗之一。然而，迄今为止，尚未有关于科兴新冠疫苗（CoronaVac®）在印度尼西亚人群中的安全性和副作用情况的报道。
在本研究中，对印度尼西亚雅加达北部一个公共卫生中心社区的科兴新冠疫苗（CoronaVac®）安全性情况进行了测定。
这是一项基于黄色表格（MESO）记录的疫苗副作用的描述性横断面问卷调查研究。纳入了2021年7月至8月期间接种科兴新冠疫苗（CoronaVac®）的300名患者。使用社会科学统计软件包（SPSS）分析描述性数据。
大多数受访者为17至21岁的女性（72.7%）。疫苗副作用（即注射部位疼痛）与女性性别之间存在显著的正相关（p = 0.009）。其他副作用，如疲劳（p = 0.034）和头痛（p < 0.001）也与疾病合并症相关。
总体而言，第一剂和第二剂疫苗接种后的副作用一般较轻，包括发热、注射部位疼痛、疲劳、头痛、嗜睡、腹泻、咳嗽和恶心。关于疫苗效力，科兴新冠疫苗（CoronaVac®）在第二剂接种后提供了更好的保护，接种第二剂后感染新冠病毒病（COVID-19）的受访者比例从26.7%降至仅20.3%。
